Biomarkers of Whole Grain Wheat and Rye Intake
Urinary Alkylresorcinol Metabolites as a Biomarker of Whole Grain Wheat and Rye Intake
1 other identifier
interventional
10
1 country
1
Brief Summary
Alkylresorcinols (AR) are a group of lipids found in the bran fraction of wheat and rye grains. AR are absorbed into the bloodstream and their metabolites are excreted in urine in measurable amounts following ingestion of wholegrain (WG) wheat or rye cereal. As AR are absent in refined cereals, plasma AR and urinary AR metabolites are proposed as suitable biomarkers of dietary intake of WG wheat and rye cereal, with a number of studies supporting this proposal. Different AR species are present in characteristic quantities in WG wheat in comparison to WG rye cereals, which can allow identification of the main source of WG (wheat or rye) in individuals by analysing the AR concentrations in blood. However the patterns of urinary AR metabolite excretion following wheat or rye intake have not yet been investigated to determine if there are differences according to WG source. The present study aims to: (i) investigate the differences in AR metabolite excretion pattern in spot and 24 hour urine samples after following a predominantly WG rye-based diet in comparison to a predominantly WG wheat-based diet and in comparison to control (refined cereal diet) (ii) compare the validity and reproducibility of AR metabolites in spot urine samples in comparison to 24 hour urine samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable healthy-volunteers
Started May 2014
Shorter than P25 for not_applicable healthy-volunteers
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 29, 2014
CompletedFirst Posted
Study publicly available on registry
June 4, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedMarch 6, 2015
March 1, 2015
4 months
May 29, 2014
March 5, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
24-h urinary DHBA:DHPPA ratio
DHBA: 3,5-dihydroxybenzoic acid DHPPA: 3-(3,5-dihydroxyphenyl)-propanoic acid DHBA \& DHPPA are the main AR metabolites excreted in urine
Endpoint (Day 3)
Secondary Outcomes (10)
DHBA:DHPPA ratio in morning spot urine
Endpoint (Day 3)
Total 24-h urinary AR metabolite (DHBA + DHPPA) excretion
Endpoint (Day 3)
Total 24-h urinary DHBA excretion
Endpoint (Day 3)
Total 24-h urinary DHPPA excretion
Endpoint (Day 3)
24-h urinary total AR (DHBA+DHPPA):creatinine ratio
Endpoint (Day 3)
- +5 more secondary outcomes
Other Outcomes (1)
Estimated daily intake of WG wheat and rye cereals
Assessed throughout each intervention period (Days 1-3)
Study Arms (3)
Whole grain rye
EXPERIMENTAL3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
Whole grain wheat
EXPERIMENTAL3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
Refined cereal
PLACEBO COMPARATORNo intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
Interventions
Eligibility Criteria
You may qualify if:
- Body mass intake 18.5-30.0 kg/m2
- Weight stable for 2 months
- Generally healthy
You may not qualify if:
- Previous or current chronic disease including heart disease, diabetes, gastrointestinal, liver, renal or endocrine disorders
- Drug or alcohol misuse in the last year
- Current pregnancy or lactation
- Weight change of \>3 kg in the last two months
- Current regular user of certain prescription medications (except contraceptives)
- Unwilling to consume or to stop consuming WG wheat, WG rye or refined cereals
- Unwilling to discontinue multivitamins/dietary supplements during study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Diabetes and Nutritional Sciences Division, King's College London
London, SW1 9NH, United Kingdom
Study Officials
- PRINCIPAL INVESTIGATOR
Julia Darzi, PhD
King's College London
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer Nutrition and Dietetics
Study Record Dates
First Submitted
May 29, 2014
First Posted
June 4, 2014
Study Start
May 1, 2014
Primary Completion
September 1, 2014
Study Completion
September 1, 2014
Last Updated
March 6, 2015
Record last verified: 2015-03